Across TCGA pan-cancer cohorts, KLK11 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated KLK11 data layer compared with 23 for mass-spec protein and 3 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher KLK11 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated KLK11 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.
PDAC, LSCC, and LUAD are the cancer types where KLK11 mass-spec protein most reproducibly stratifies survival.